Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

Original reporting
Published Nov 17, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ACAD
Bullish
medium confidence
Mentioned
$ACAD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACADBullishMed
01

Why it matters

The update highlights additional efficacy signals for the 60 mg dose on CGI-I-ADP and NPI/NPI-NH psychosis measures, alongside safety/tolerability similar to placebo, which can shift sentiment toward the Phase 3 program.

02

Market read

Conference-published secondary and exploratory efficacy improvements for the 60 mg dose can drive short-term re-rating of the clinical program, but the earlier primary endpoint miss remains a key overhang.

03

What to watch

Traders may discount nominal p-values and subgroup threshold effects if multiplicity and prespecification are unclear, and will likely wait for Phase 3 readouts rather than conference add-ons.

Relevance 7/10Novelty 6/10Timing: conference-day update, likely to influence near-term biotech sentiment and positioning

Background

Acadia’s remlifanserin is being studied in Phase 2 RADIANT for Alzheimer’s disease psychosis, with Phase 3 advancement underway.

Company-level read

Ticker impact

$ACADBullishMedium confidence
Context

Acadia presented new Phase 2 RADIANT analyses for remlifanserin, including CGI-I-ADP separation at Weeks 2, 4, and 6 and Week 6 responder rates vs placebo.

Expected impact

Likely modest upward bias as traders re-rate the program on added efficacy signals, while remaining cautious due to the earlier primary endpoint narrowly missing.

Evidence & confidence

The article adds specific nominal p-values and responder-rate comparisons for the 60 mg dose, plus safety being similar to placebo, but it does not report a new primary endpoint win or regulatory decision.

Market effects

Reinforces investor focus on Alzheimer’s disease psychosis trial read-throughs and the value of secondary endpoint and subgroup threshold analyses in biotech risk models.

Limited, primarily affects US-listed biotech sentiment rather than broader regional risk.

Low, as the catalyst is company-specific clinical-trial data presented at a conference.

Counterpoint

Because the primary endpoint was still narrowly missed, the new analyses may be viewed as post-hoc or exploratory, limiting how much the market should re-rate Phase 3 success probability.

Key entities

  • Acadia Pharmaceuticals Inc.

    NASDAQ-listed developer of remlifanserin for Alzheimer’s disease psychosis; presented additional Phase 2 RADIANT analyses.

  • remlifanserin

    Acadia’s investigational therapy evaluated in Phase 2 RADIANT and also in a Phase 2 study for Lewy body dementia psychosis.

  • RADIANT trial

    Phase 2 program in Alzheimer’s disease psychosis; new analyses presented at the Clinical Trials on Alzheimer’s Disease conference.

Related articles

$ACADHighAI 8/10

Acadia Pharma (ACAD) Q3 2026 Earnings Call Transcript

Acadia Pharma (ACAD) reported Q3 2026 total revenues of $342M, up 22% YoY. DAYBUE sales reached $140M, up 39% YoY, leading to raised 2026 guidance. NUPLAZID sales grew 12% YoY to $202M. The company extended DAYBUE patent protection to 2041 and plans a 2027 regulatory submission in Japan. Pipeline updates include remlifanserin and ACP-211, with peak sales potential of $11B.

$ACADHighAI 8/10

RBC raises Acadia Pharmaceuticals stock price target on Daybue growth

RBC Capital raised its price target for Acadia Pharmaceuticals (ACAD) to $38, citing strong Daybue uptake and growth potential. The firm expects European launch and pipeline readouts to drive future sales. Acadia reported Q3 2026 earnings of $0.31 per share, beating estimates, with revenue of $342 million. Daybue sales grew 39% YoY to $140 million, while Nuplazid sales increased 12% to $202 million. The company narrowed its 2026 revenue guidance to $1.265B-$1.295B.